Bioavailability (BA) and bioequivalence (BE) studies are required of new as well as generic drug products. BA/BE are parameters with practical and public health value for drug manufacturers, for regulatory agencies, and ultimately for patients. From a drug product performance perspective, BA studies also benchmark the performance of the formulation(s) … Continue Reading
Theme: Breaking New Grounds for Pharmacy Service in Primary Health Care
Theme: Health Technology Assessment: Impact on Health Care and Assessment of the Value of Medicines Organizers: ISPOR Hong Kong Chapter and The Chinese University of Hong Kong Co-organizers: ISPOR Asia Consortium, Shanghai Chapter and Beijing Chapters
Date: 25 June 2015 (Thursday) Venue: G02, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39 , CUHK Time: 08:45a.m. – 5:00p.m. Customizing drug delivery to treat patients burdened with a myriad of diseases in a therapeutically and cost effective manner while meeting the vigorous regulatory standards of quality is a formidable challenge … Continue Reading
Enquiry: Kate CHEUNG / (852) 3943-6831 / sop.med@pharmacy.cuhk.edu.hk Download the Programme / Abstracts / Power Point Files BABE Workshop Programme and Abstracts Vinod P. SHAH Implementation of BABE Requirements at the FDA-Lessons Learned Immediate Release and Modified Release Bioequivalence Requirements Biowaivers – BCS and IVIVC Design and Regulatory Assessment of Transdermal Drug … Continue Reading
Subscribe to filtered calendar